Thelansis

MECP2 Duplication Syndrome (MDS) Market Outlook Thelansis’s “MECP2 Duplication Syndrome (MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential MECP2 Duplication Syndrome (MDS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest im...

  MECP2 Duplication Syndrome (MDS) Market Outlook Thelansis’s “MECP2 Duplication Syndrome (MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential MECP2 Duplication Syndrome (MDS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). MECP2 Duplication Syndrome (MDS) Overview MECP2 duplication syndrome, an X-linked neurodevelopmental disorder, predominantly affects males and presents with characteristics including intellectual disability, autistic features, treatment-resistant epilepsy, and a progression from infantile hypotonia to lower-limb spasticity. This syndrome is marked by early-onset hypotonia, feeding difficulties, gastrointest...

  MECP2 duplication syndrome, an X-linked neurodevelopmental disorder, predominantly affects males and presents with characteristics including intellectual disability, autistic features, treatment-resistant epilepsy, and a progression from infantile hypotonia to lower-limb spasticity. This syndrome is marked by early-onset hypotonia, feeding difficulties, gastrointestinal issues like gastroesophageal reflux and constipation, delayed psychomotor development leading to severe intellectual disability, limited speech development, progressive spasticity, recurrent respiratory infections in approximately 75% of affected individuals, and seizures in about 50% of cases. It is fully penetrant in males, although occasional females have been reported with varying degrees of intellectual disability, from mild to a phenotype similar to that of affected males. Additionally, several affected boys exhibit autistic behaviors, nonspecific neuroimaging findings on brain MRI, mottled skin, and uroge...